FLUCONAZOLE (fluconazole) by Ichnos Glenmark Innovation is cytochrome p450 2c19 inhibitors [moa]. Approved for azole antifungal [epc]. First approved in 2006.
Drug data last refreshed 19h ago
Cytochrome P450 2C19 Inhibitors
Azole Antifungal
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
Worked on FLUCONAZOLE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo